Cargando…
Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis
BACKGROUND: Hospitals expanded critical care capacity during the COVID-19 pandemic by treating COVID-19 patients with high-flow nasal cannula oxygen therapy (HFNC) in non-traditional settings, including general internal medicine (GIM) wards. The impact of this practice on intensive care unit (ICU) c...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854405/ https://www.ncbi.nlm.nih.gov/pubmed/36662403 http://dx.doi.org/10.1007/s11606-022-07949-9 |
_version_ | 1784873111106093056 |
---|---|
author | Silverstein, William K. Zipursky, Jonathan S. Amaral, Andre C. Leis, Jerome A. Strong, Laura Nardi, Julie Weinerman, Adina S. Wong, Brian M. Stroud, Lynfa |
author_facet | Silverstein, William K. Zipursky, Jonathan S. Amaral, Andre C. Leis, Jerome A. Strong, Laura Nardi, Julie Weinerman, Adina S. Wong, Brian M. Stroud, Lynfa |
author_sort | Silverstein, William K. |
collection | PubMed |
description | BACKGROUND: Hospitals expanded critical care capacity during the COVID-19 pandemic by treating COVID-19 patients with high-flow nasal cannula oxygen therapy (HFNC) in non-traditional settings, including general internal medicine (GIM) wards. The impact of this practice on intensive care unit (ICU) capacity is unknown. OBJECTIVE: To describe how our hospital operationalized the use of HFNC on GIM wards, assess its impact on ICU capacity, and examine the characteristics and outcomes of treated patients. DESIGN: Retrospective cohort study of all patients treated with HFNC on GIM wards at a Canadian tertiary care hospital. PARTICIPANTS: All patients admitted with COVID-19 and treated with HFNC on GIM wards from December 28, 2020, to June 13, 2021, were included. MAIN MEASURES: We combined administrative data on critical care occupancy daily with chart-abstracted data for included patients to establish the total number of patients receiving ICU-level care at our hospital per day. We also collected data on demographics, medical comorbidities, illness severity, COVID-19 treatments, HFNC care processes, and patient outcomes. KEY RESULTS: We treated 124 patients with HFNC on the GIM wards (median age 66 years; 48% female). Patients were treated with HFNC for a median of 5 days (IQR 3 to 8); collectively, they received HFNC for a total of 740 hospital days, 71% of which were on GIM wards. At peak ICU capacity strain (144%), delivering HFNC on GIM wards added 20% to overall ICU capacity by managing up to 14 patients per day. Patients required a median maximal fraction of inspired oxygen of 80% (IQR 60 to 95). There were 18 deaths (15%) and 85 patients (69%) required critical care admission; of those, 40 (47%) required mechanical ventilation. CONCLUSIONS: With appropriate training and resources, treatment of COVID-19 patients with HFNC on GIM wards appears to be a feasible strategy to increase critical care capacity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-022-07949-9. |
format | Online Article Text |
id | pubmed-9854405 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-98544052023-01-23 Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis Silverstein, William K. Zipursky, Jonathan S. Amaral, Andre C. Leis, Jerome A. Strong, Laura Nardi, Julie Weinerman, Adina S. Wong, Brian M. Stroud, Lynfa J Gen Intern Med Original Research BACKGROUND: Hospitals expanded critical care capacity during the COVID-19 pandemic by treating COVID-19 patients with high-flow nasal cannula oxygen therapy (HFNC) in non-traditional settings, including general internal medicine (GIM) wards. The impact of this practice on intensive care unit (ICU) capacity is unknown. OBJECTIVE: To describe how our hospital operationalized the use of HFNC on GIM wards, assess its impact on ICU capacity, and examine the characteristics and outcomes of treated patients. DESIGN: Retrospective cohort study of all patients treated with HFNC on GIM wards at a Canadian tertiary care hospital. PARTICIPANTS: All patients admitted with COVID-19 and treated with HFNC on GIM wards from December 28, 2020, to June 13, 2021, were included. MAIN MEASURES: We combined administrative data on critical care occupancy daily with chart-abstracted data for included patients to establish the total number of patients receiving ICU-level care at our hospital per day. We also collected data on demographics, medical comorbidities, illness severity, COVID-19 treatments, HFNC care processes, and patient outcomes. KEY RESULTS: We treated 124 patients with HFNC on the GIM wards (median age 66 years; 48% female). Patients were treated with HFNC for a median of 5 days (IQR 3 to 8); collectively, they received HFNC for a total of 740 hospital days, 71% of which were on GIM wards. At peak ICU capacity strain (144%), delivering HFNC on GIM wards added 20% to overall ICU capacity by managing up to 14 patients per day. Patients required a median maximal fraction of inspired oxygen of 80% (IQR 60 to 95). There were 18 deaths (15%) and 85 patients (69%) required critical care admission; of those, 40 (47%) required mechanical ventilation. CONCLUSIONS: With appropriate training and resources, treatment of COVID-19 patients with HFNC on GIM wards appears to be a feasible strategy to increase critical care capacity. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11606-022-07949-9. Springer International Publishing 2023-01-20 2023-04 /pmc/articles/PMC9854405/ /pubmed/36662403 http://dx.doi.org/10.1007/s11606-022-07949-9 Text en © The Author(s), under exclusive licence to Society of General Internal Medicine 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
spellingShingle | Original Research Silverstein, William K. Zipursky, Jonathan S. Amaral, Andre C. Leis, Jerome A. Strong, Laura Nardi, Julie Weinerman, Adina S. Wong, Brian M. Stroud, Lynfa Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis |
title |
Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis
|
title_full |
Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis
|
title_fullStr |
Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis
|
title_full_unstemmed |
Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis
|
title_short |
Effect of Ward-Based High-Flow Nasal Cannula (HFNC) Oxygen Therapy on Critical Care Utilization During the COVID-19 Pandemic: A Retrospective Cohort Analysis
|
title_sort | effect of ward-based high-flow nasal cannula (hfnc) oxygen therapy on critical care utilization during the covid-19 pandemic: a retrospective cohort analysis |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854405/ https://www.ncbi.nlm.nih.gov/pubmed/36662403 http://dx.doi.org/10.1007/s11606-022-07949-9 |
work_keys_str_mv | AT silversteinwilliamk effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis AT zipurskyjonathans effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis AT amaralandrec effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis AT leisjeromea effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis AT stronglaura effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis AT nardijulie effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis AT weinermanadinas effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis AT wongbrianm effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis AT stroudlynfa effectofwardbasedhighflownasalcannulahfncoxygentherapyoncriticalcareutilizationduringthecovid19pandemicaretrospectivecohortanalysis |